These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

49 related articles for article (PubMed ID: 7622541)

  • 1. Preservation of surface-dependent properties of viral antigens following immobilization on particulate ceramic delivery vehicles.
    Kossovsky N; Gelman A; Sponsler E; Rajguru S; Torres M; Mena E; Ly K; Festekjian A
    J Biomed Mater Res; 1995 May; 29(5):561-73. PubMed ID: 7622541
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recombinant human immunodeficiency Pr55gag virus-like particles presenting chimeric envelope glycoproteins induce cytotoxic T-cells and neutralizing antibodies.
    Deml L; Schirmbeck R; Reimann J; Wolf H; Wagner R
    Virology; 1997 Aug; 235(1):26-39. PubMed ID: 9300034
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Specificity of humoral and cellular immune response against recombinant particles of nucleocapsid protein of human hepatitis B virus in rabbits.
    Isaguliants MG; Kadoshnikov YP; Kalinina TI; Smirnov VD; Wahren B
    Biochemistry (Mosc); 1998 May; 63(5):551-8. PubMed ID: 9632891
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hemagglutinating virus of Japan protein is efficient for induction of CD4+ T-cell response by a hepatitis B core particle-based HIV vaccine.
    Takeda S; Shiosaki K; Kaneda Y; Nakasatomi T; Yoshizaki H; Someya K; Konno Y; Eda Y; Kino Y; Yamamoto N; Honda M
    Clin Immunol; 2004 Jul; 112(1):92-105. PubMed ID: 15207786
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunogenic and antigenic dominance of a nonneutralizing epitope over a highly conserved neutralizing epitope in the gp41 envelope glycoprotein of human immunodeficiency virus type 1: its deletion leads to a strong neutralizing response.
    Cleveland SM; Buratti E; Jones TD; North P; Baralle F; McLain L; McInerney T; Durrani Z; Dimmock NJ
    Virology; 2000 Jan; 266(1):66-78. PubMed ID: 10612661
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development of HIV/AIDS vaccine using chimeric gag-env virus-like particles.
    Kang CY; Luo L; Wainberg MA; Li Y
    Biol Chem; 1999 Mar; 380(3):353-64. PubMed ID: 10223338
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rational design of a plasmid DNA vaccine capable of eliciting cell-mediated immune responses to multiple HIV antigens in mice.
    Egan MA; Megati S; Roopchand V; Garcia-Hand D; Luckay A; Chong SY; Rosati M; Sackitey S; Weiner DB; Felber BK; Pavlakis GN; Israel ZR; Eldridge JH; Sidhu MK
    Vaccine; 2006 May; 24(21):4510-23. PubMed ID: 16140439
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Enhanced mucosal and systemic immune response with intranasal immunization of mice with HIV peptides entrapped in PLG microparticles in combination with Ulex Europaeus-I lectin as M cell target.
    Manocha M; Pal PC; Chitralekha KT; Thomas BE; Tripathi V; Gupta SD; Paranjape R; Kulkarni S; Rao DN
    Vaccine; 2005 Dec; 23(48-49):5599-617. PubMed ID: 16099080
    [TBL] [Abstract][Full Text] [Related]  

  • 9. AIDS vaccine: Intranasal immunization using inactivated HIV-1-capturing core-corona type polymeric nanospheres.
    Akagi T; Ueno M; Hiraishi K; Baba M; Akashi M
    J Control Release; 2005 Dec; 109(1-3):49-61. PubMed ID: 16256237
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Use of DNAs expressing HIV-1 Env and noninfectious HIV-1 particles to raise antibody responses in mice.
    Lu S; Santoro JC; Fuller DH; Haynes JR; Robinson HL
    Virology; 1995 May; 209(1):147-54. PubMed ID: 7747464
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The adjuvancy of OX40 ligand (CD252) on an HIV-1 canarypox vaccine.
    Liu J; Ngai N; Stone GW; Yue FY; Ostrowski MA
    Vaccine; 2009 Aug; 27(37):5077-84. PubMed ID: 19573639
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of human immunodeficiency virus type 1 subtype C gag, pol, and gagpol DNA and alphavirus replicon vaccines.
    Megede JZ; Otten GR; Doe B; Liu H; Srivastava R; Greer C; Legg H; Tang T; Polo JM; Donnelly JJ; Ulmer JB; Barnett SW
    Vaccine; 2006 Apr; 24(15):2755-63. PubMed ID: 16460840
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antigenic properties of recombinant envelope glycoproteins derived from T-cell-line-adapted isolates or primary human immunodeficiency virus isolates and their relationship to immunogenicity.
    Brand D; Lemiale F; Thibault G; Verrier B; Lebigot S; Roingeard P; Buzelay L; Brunet S; Barin F
    Virology; 2000 Jun; 271(2):350-62. PubMed ID: 10860888
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A DNA vaccine containing inverted terminal repeats from adeno-associated virus increases immunity to HIV.
    Xin KQ; Ooki T; Jounai N; Mizukami H; Hamajima K; Kojima Y; Ohba K; Toda Y; Hirai S; Klinman DM; Ozawa K; Okuda K
    J Gene Med; 2003 May; 5(5):438-45. PubMed ID: 12731092
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Induction of systemic and mucosal cross-clade neutralizing antibodies in BALB/c mice immunized with human immunodeficiency virus type 1 clade A virus-like particles administered by different routes of inoculation.
    Buonaguro L; Visciano ML; Tornesello ML; Tagliamonte M; Biryahwaho B; Buonaguro FM
    J Virol; 2005 Jun; 79(11):7059-67. PubMed ID: 15890945
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Strong cellular and humoral anti-HIV Env immune responses induced by a heterologous rhabdoviral prime-boost approach.
    Tan GS; McKenna PM; Koser ML; McLinden R; Kim JH; McGettigan JP; Schnell MJ
    Virology; 2005 Jan; 331(1):82-93. PubMed ID: 15582655
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficient expansion of HIV-1-specific T cell responses by homologous immunization with recombinant Semliki Forest virus particles.
    Sundbäck M; Douagi I; Dayaraj C; Forsell MN; Nordström EK; McInerney GM; Spångberg K; Tjäder L; Bonin E; Sundström M; Liljeström P; Karlsson Hedestam GB
    Virology; 2005 Oct; 341(2):190-202. PubMed ID: 16098555
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Design of immunogens that present the crown of the HIV-1 V3 loop in a conformation competent to generate 447-52D-like antibodies.
    Chakraborty K; Durani V; Miranda ER; Citron M; Liang X; Schleif W; Joyce JG; Varadarajan R
    Biochem J; 2006 Nov; 399(3):483-91. PubMed ID: 16827663
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Designing and engineering of DNA-vaccine construction encoding multiple CTL-epitopes of major HIV-1 antigens.
    Bazhan SI; Belavin PA; Seregin SV; Danilyuk NK; Babkina IN; Karpenko LI; Nekrasova NA; Lebedev LR; Ignatyev GM; Agafonov AP; Poryvaeva VA; Aborneva IV; Ilyichev AA
    Vaccine; 2004 Apr; 22(13-14):1672-82. PubMed ID: 15068850
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ancestral and consensus envelope immunogens for HIV-1 subtype C.
    Kothe DL; Li Y; Decker JM; Bibollet-Ruche F; Zammit KP; Salazar MG; Chen Y; Weng Z; Weaver EA; Gao F; Haynes BF; Shaw GM; Korber BT; Hahn BH
    Virology; 2006 Sep; 352(2):438-49. PubMed ID: 16780913
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.